

<SEC-DOCUMENT>0001144204-19-013521.txt : 20190312
<SEC-HEADER>0001144204-19-013521.hdr.sgml : 20190312
<ACCEPTANCE-DATETIME>20190312161552
ACCESSION NUMBER: 0001144204-19-013521
CONFORMED SUBMISSION TYPE: 6-K
PUBLIC DOCUMENT COUNT: 3
CONFORMED PERIOD OF REPORT: 20190312
FILED AS OF DATE: 20190312
DATE AS OF CHANGE: 20190312

FILER:

COMPANY DATA:

COMPANY CONFORMED NAME: Anchiano Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231

FILING VALUES:

FORM TYPE: 6-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 19675240

BUSINESS ADDRESS:

STREET 1: 1/3 HIGH-TECH VILLAGE
STREET 2: GIVAT RAM, P.0. BOX 39264
CITY: JERUSALEM
STATE: L3
ZIP: 9139102
BUSINESS PHONE: 972-2-5486555

MAIL ADDRESS:

STREET 1: 1/3 HIGH-TECH VILLAGE
STREET 2: GIVAT RAM, P.0. BOX 39264
CITY: JERUSALEM
STATE: L3
ZIP: 9139102

FORMER COMPANY:

FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104

</SEC-HEADER>

<DOCUMENT>

<TYPE>6-K

<SEQUENCE>1

<FILENAME>tv516074_6k.htm

<DESCRIPTION>FORM 6-K

<TEXT>

<HTML>

<HEAD>

<TITLE></TITLE>

</HEAD>

<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV
STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width:
100%"> </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"> </P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">FORM 6-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPORT OF
FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>For
the month of March 2019</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV
STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"> </DIV></DIV><!-- Field: /Rule-
Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT
STYLE="font-size: 14pt; text-transform: uppercase">Anchiano
Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation
of registrant's name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV
STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"> </DIV></DIV><!-- Field: /Rule-
Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1/3 High-Tech Village, Givat Ram, P.O. Box 39264</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jerusalem, 9139102 Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"> </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

<TR STYLE="vertical-align: top">

<TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt">Form 20-F	x</TD>

<TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt">Form 40-F	¨</TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

<TR STYLE="vertical-align: top">

<TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt">Yes	¨</TD>

<TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt">No	x</TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%"> </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, Anchiano Therapeutics Ltd. announced its fourth quarter and full year 2018 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<TR STYLE="vertical-align: top; background-color: white">

<TD STYLE="width: 13%; padding: 0; font-size: 10pt; text-indent: 0"><U>Exhibit No.</U></TD>

<TD STYLE="width: 87%; padding: 0; font-size: 10pt; text-indent: 0"><U>Description of Exhibit</U></TD></TR>

<TR STYLE="vertical-align: top; background-color: white">

<TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"> </TD>

<TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"> </TD></TR>

<TR STYLE="vertical-align: top; background-color: white">

<TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">99.1</TD>

<TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">Press Release dated March 12, 2019</TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">Anchiano Therapeutics Ltd. </TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD></TR>

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-indent: 0; width: 50%"> </TD>

<TD STYLE="padding: 0; text-indent: 0; width: 5%"> </TD>

<TD STYLE="padding: 0; text-indent: 0; width: 30%"> </TD>

<TD STYLE="padding: 0; text-indent: 0; width: 15%"> </TD></TR>

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0">By:</TD>

<TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ Dr. Frank G.

Haluska</TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD></TR>

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0">Dr. Frank G. Haluska</TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD></TR>

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0">Chief Executive Officer</TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD></TR>

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-indent: 0"> </TD></TR>

<TR STYLE="vertical-align: top">

<TD STYLE="padding: 0; text-align: left; text-indent: 0">Dated March 12, 2019</TD>

<TD STYLE="padding: 0; text-align: left; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-align: left; text-indent: 0"> </TD>

<TD STYLE="padding: 0; text-align: left; text-indent: 0"> </TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P

STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>

</HTML>

</TEXT>

</DOCUMENT>

<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv516074_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"> </P>

<P STYLE="margin: 0; text-align: right">Exhibit 99.1</P>

<P STYLE="margin: 0"> </P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG
SRC="image_001.jpg" ALT="Anchiano Therapeutics" STYLE="height: 65px; width: 310px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR IMMEDIATE RELEASE </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Anchiano
Therapeutics Reports Fourth
Quarter and Full Year 2018 Financial Results</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>–
Successfully Completed \$30.5
million U.S. Initial Public Offering in February 2019 –</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>–
Interim Analysis of the Codex
Clinical Trial Expected in Fourth Quarter 2019 –</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CAMBRIDGE,
Mass., March 12, 2019
- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage
biopharmaceutical company focused
on the discovery and development of novel therapies to treat cancer, today reported financial results
for its fourth quarter and
year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-
color: white">Key Developments
and Recent Highlights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top"><TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">·</TD><TD STYLE="text-align: justify">Closed an initial public offering (“IPO”) on February 14, 2019, resulting in gross proceeds of \$30.5 million. The ADSs began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN”. The net proceeds from Anchiano’s IPO are held in cash and cash equivalents and are expected to fund operations until the end of the second quarter of 2020. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top"><TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">·</TD><TD STYLE="text-align: justify">Initiated its Codex Clinical Trial in December 2018 for the development of its lead product candidate inodiftagene vixteplasmid (“inodiftagene”), a recombinant DNA construct designed to be administered to patients with early stage bladder cancer. The single-arm, open label study is designed to test the effects of inodiftagene in a setting unresponsive to bacillus Calmette-Guérin (“BCG”). An interim analysis of the Codex Clinical Trial is expected to be completed during the fourth quarter of 2019. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fourth Quarter and Full Year 2018 Financial Results:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt; text-align: left">·</TD><TD STYLE="text-align: justify">On December 31, 2018, Anchiano had total cash and cash equivalents of approximately \$7.5 million, compared to approximately \$1.5 million on December 31, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt; text-align: left">·</TD><TD STYLE="text-align: justify">Research and development expenses incurred in the fourth quarter and fiscal year ended December 31, 2018, respectively, were approximately \$1.8 million and \$7.6 million, compared to approximately \$1.0 million and \$6.2 million incurred in

the fourth quarter and fiscal year ended December 31, 2017, respectively. This increase was mainly due to an increase in clinical trial initiation expenses, manufacturing expenses and an increase in clinical manpower.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </P>

	•</TD><TD style="text-align: justify">General and administrative expenses incurred in the fourth quarter and fiscal year ended December 31, 2018, respectively, were approximately \$1.2 million and \$5.5 million, compared to approximately \$0.9 million and \$3.2 million incurred in the fourth quarter and fiscal year ended December 31, 2017, respectively. This increase was mainly due to an option grant to our Chief Executive Officer and increases in payroll provisions, professional and consulting expenses and rent expenses.</TD></TR></TABLE>
--	---

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </P>

	•</TD><TD style="text-align: justify">Financing (income) expense, net, in the fourth quarter and fiscal year ended December 31, 2018, respectively, was approximately \$(1.3) million and \$(0.4) million, compared to approximately \$(0.05) million and \$0.1 million in the fourth quarter and fiscal year ended December 31, 2017, respectively. This change was due to issuance costs related to the derivative financial instruments issued in the second quarter of 2018, changes in the fair value of derivative financial instruments, and exchange rate fluctuations.</TD></TR></TABLE>
--	---

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </P>

	•</TD><TD style="text-align: justify">In summary, net loss for the fourth quarter and fiscal year ended December 31, 2018, respectively, was approximately \$1.8 million and \$13.3 million, compared to approximately \$1.9 million and \$9.8 million in the fourth quarter and fiscal year ended December 31, 2017.</TD></TR></TABLE>
--	---

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">About Anchiano</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Anchiano is a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. Anchiano's most advanced product candidate, inodiftagene, is in development as a treatment for non-muscle-invasive bladder cancer. For more information on Anchiano, please visit <U>www.anchiano.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #263F6A"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains "forward-looking statements" that are subject to risks and uncertainties. Words such as "believes," "intends," "expects," "projects," "anticipates" and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of Anchiano, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including, when filed, its Annual Report on Form 20-F for the year ended December 31, 2018. Anchiano undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Frank Haluska,
M.D., Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">President and
Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>info@anchiano.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Investor Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Ashley R. Robinson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">LifeSci Advisors,
LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">617-535-7742</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>arr@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<!-- Field: Page; Sequence: 2 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">QUARTERLY RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. dollars in thousands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Fiscal Quarter Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD></TR>

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom:

1pt"> </TD>
<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Operating expenses:</TD><TD STYLE="font-size: 10pt"> </TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> </TD><TD STYLE="font-size: 10pt"> </TD><TD STYLE="font-size: 10pt"> </TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"> </TD><TD STYLE="font-size: 10pt"> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Research and development expenses</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> </TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,837</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> </TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,007</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">General and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,139</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">875</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,976</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,882</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Financing income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,327</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(47</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Loss before taxes on income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD></TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,649</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman,

Times, Serif"> </TD>

<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,835</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Income tax</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">160</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">113</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </TD>

<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,809</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </TD>

<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,948</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. dollars in thousands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Fiscal Quarter Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD></TR>

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD></TR>

Net cash used in operating activities	 	(3,521)	(1,889)
Net cash used in investing activities	 	(26)	(8)
Net cash provided by financing activities	 	-	 	 	
Net increase (decrease) in cash and cash equivalents	 	(3,547)	 	

<!-- Field: Page; Sequence: 3 -->

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. dollars in thousands, except for per share data </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

Fiscal Year Ended December 31,	
2018	2017
Consolidated Statements of Operations:	
Operating expenses:	
Research and development expenses	7,559
 	
 	6,229

General and administrative expenses	
 	5,485
 	
 	3,163
 	
Operating loss	
 	13,044
 	
 	9,392
 	
 	
Financing expense (income), net	
 	(386)
 	
 	91
 	
Loss before taxes on income	
 	12,658
 	
 	9,483
 	
Income tax	
 	621
 	
 	323

Net loss	
13,279	
9,806	
Net loss per ordinary share	
1.05	
1.09	

Fiscal Year Ended December 31,					
2018		2017			
Consolidated Statements of Financial Position Data:					

Cash and cash equivalents		7,517		1,454
Working capital		884		(842)
Total assets		12,574		2,087
Total liabilities		13,664		2,696
Total shareholders' equity (deficiency)		(1,090)		(609)

</P>

</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. dollars in thousands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

2018		2017	
Net cash used in operating activities	(14,744)	(8,515)	(338)
Net cash used in by investing activities	93	(34)	(5,242)
Net cash provided by financing activities	1,622	21,162	1,622

2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">Net increase (decrease) in cash and cash equivalents	</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </TD>

<TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">6,080</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </TD>

<TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(3,307</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="margin: 0"></P>

</BODY>

</HTML>

</TEXT>

</DOCUMENT>

<DOCUMENT>

<TYPE>GRAPHIC

<SEQUENCE>3

<FILENAME>image_001.jpg

<DESCRIPTION>GRAPHIC

<TEXT>

begin 644 image_001.jpg

M_]C_X 02D9)1@ ! 0\$ 8 !@ #_VP!# H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0\$!))C!&2T4^2CD_0#W_
MVP!# 0L+"P\ -#QT0\$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3W_P 1" !! 38# 2(A\$! Q\$!_0
M'P 04! 0\$! 0\$ \$" P0%!@("&0H+_ \0 M1 @\$# P(\$ P4%
M! 0 %] 0(# 01!1(A,4\$&\$U%A!R)Q%#!D:\$((T*QP152T? D,V)R@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P\$ P\$! 0\$!
M 0\$! 0 \$" P0%!@("&0H+_ \0 M1\$ @\$"! 0#! <%! 0 0)W \$"
M Q\$\$!2\$Q!A)!40=A<1,B,H\$(%\$*1H;'!"2,S40 58G+1"A8D-.\$E\1<8&1HF
M)R@I*C4V-S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI: :GJ*FJLK.TM; :WN+FZPL/\$Q<;'R,G*TM/4
MU=;7V-G: XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q\$ /P#V:BBF2R)#
M\$\DC!412S,>@ ZF@#.NO\$NE66M6^DW-XB7]P 8H2#ELYQSC Z'K6I7SCXFGU
M/4;W_A,EREO<7K1VK=T\O&S^7Y@U[[H&KQZ[H5GJ4.-MQ\$(' \ +=Q^!R*VJ4
MN1)C:L:-%%&8B"BBFJZMG:P..N#0 ZBBB@ HIK.J?>8+]3BES0!AZQXTT+0+
MS[+JE\+>;&P8G(P>G(&.U6=#\2:9XDBFETFY^T1PML=@C* <9[@5'XMMXKG
MPEJR31K(OV25L,,\A20?SKA_@7_R -3_ .OH?^@"M5"+IN75#MH>H44W>N[;
MN&[TSS3JR\$(S!5+,0% R2>U16MW;WL/FVD\4\><;XG##/U%5M<TM=;T2\TYI
M7A6YB,9D3JN>]8?@'P4!>G7,#WGVJ2XD#L0FU5P,# R?QJDERWOJ!U=%-9
MU3&Y@,^IJO'44F:6@ HHI"0!DG H 6BD5E894@CU!I: "BBF[U+;=PW>F>:
M'4444 %%% #7)",5&Y@.!ZUS!\67UF?^)IH5U"@/,D1W@5U-03S"/Y5Y<_I

M51:6ZN3)-[.Q4TSQ!IVK%G<JS]XV^5Q^!K2K\$U3PKI^J?O/+^SW0Y\$/RL#
M[^M9UOK- _P'' ;I++Q ?-MG.V&^4?HW^?SJ^2,Q0^XGF<?B^ \ZRBFP90RD\$\$
M9!>G5D:!1110 5Q7Q0U6:V\ /1Z38Y-]J\HM8E'7:?'0']0/QKM:\JN=/NOB%
M\0KZ>SU&6QM=\$ @N(EW'S.=V.?KS["M*25[09#1U&N>#(;CX<MH%LH+V\ ,
M!QUD7G/XG/YUROP2UTO;7NASMAXC]HA!ZX/#C\#@_B:W?^\$!US_H>=7_ .^?
M_LJ\ \0; .X^&?Q(LYY;A[B!B)6F9=IEC?B3(]0<_I6T\$I1<+WZC6NA[[7E0Q0
MT!M'T>76M.U75(9FN!YD?VMRA#GL, \8/I7J".LB*Z\$,K#([BN'^,7_(@S?])
M? \$?_ *%6-%VFA+<YWPO::SX^\ /6EFVH7-AH]F@BFD1LRW<05N?[HR/\ /2EX
MP^'\0@C3UUS0-5008'42!WPRY. P(QGG&01WK00AA&L?P\TG8 -R.Q]R7:H_
MBG_R305/I'_Z&M:JHU4Y5M<=]31\%:[)XC\)V.HS@">12LNT8&]203^.,_C6
M) \3/'\$GA33XK73]IU* [!V,1GRD'5L=SG@?\ UJD^\$?\ R3ZS_P"ND0\ Z&:X
M;XA_Q_C!I\5S_J0ULHSTVELG]2:4()U6NB!+4Z#00A9_:EHFH>+K^NKZ<!S
M%YQ_CSV)ZD_D*I>-0"-_X1T.2\ \.ZQJ,>G[E6YM7G)V@D ,I[<XS7K=0W5M!
M>6[P744<L+C#I(H*L/<H5:5[L5S/\0^\\$=3_P"0&7_T UXY\ -FUC5- /NM T
M68V2S2B>[OAR8H]H4*0^T3F09?\$H *ZKCI]CEQ_WP:X'X%1J-\$U23'SM<*I
M/L%X_F:NF[4Y,:V(M<^#\=GI<])I>K757\"&4&9Q^\ (&2,C!K9^\$GBB[\0Z
M#<0:A*TUQ92*HE8_,Z, ,C/J1@C=-MJ'_ "#KG_KDW\C7EGP(_P!3K7^)#_]J
M.9SIOFZ!NCM/&'AB/5[.X0%0]0M+J&W;RS;W#(G&2,J.#7+?!^*NKZRU=[NY
MFG821 &60N1I]:]\$U?_) U]_U[R?\ H)KS3X\$?\ @_6/^NL7_H)I1=Z40D'
M0Z3XG>*KOPOX<1]/PMU=2>2DI&1'P23]>.*RO!_A#P]XI\ -6VJZ+54;JX4^
M=+=30N#@X8 XQGI6W\00\$NC:#I"1ZQ9IJ#7!_ =6C*"&(_B)/0#/7WK#T:Y\
M<ZW8PC3;+3?#VF[?W6Z<X7MM7_\$"B-_9Z:>8=#"U.2Y^&GCZPM=+OKB73+S
M8SVDTA<*I;:15^8->QRQB6)XV) =2I*G!Y]#7A/CW1?[%\8:,DU]/?WD^R2X
MN)CRQ\ S P.B@ <"O>-PW;<C=C., \T5MHL3/\$OB=I,WA.XT]M.U?5?(N@X>.6
M[=L%<=#GOFNDM_#FH_\$:W34]90[JPTMQ_H=C;M@E.SN>Y/7I69\=_NZ*/>;_
M -DKU33HUBTRUC085(44 =@ *J4VJ<7U&WH>*^)M%U#X5:K9:AHVI7\$MI,Q!
M20]2.2K <\$=\$\5[9972WMC;W2#"3QK(H)B,_UK57XZ_\@+3/^OEO_0#7;Z87
M7P1:&+/F#3D*X]?+&*FH^:\$9/<'JC@=4\1:IX^\9MX<T*\>RTN M]HN(N'=5
M.&. ?3/ ' ?J:Z!_A)X>-L5B:^BN<<70N6+Y]?3]*Y'X%A#J>KLW^M\F/&>N-Q
MS^N*]FIU6Z<N6/0'H>6>\$0>J^'0&#^\$0\$EP;I2^RVN7^]DC*Y/< ,/7D&04Z
M\1^*W[OXE:8]0_K_ "H#QUW>8<5[=4U4K*2ZB8444R618HR['@5B(9<3B"//
M5CPH]:K6ZY8R2G..2?>H@6GE,C_@/04L\ \<46Z61(H5ZL[!1]>T!>QHHV] W
M8U#>V4&H6DEM=1B2*08(\^>M8\$WC2V8^1I%0)>NO'F?<B'U8_P!4EBVJ:H^
MZ>?9'_\$(AM4>P[DTN:ST,0:QEI'4KZ'<3Z#JQT&^D+PN-UE*W=?[O^?*ZJL
M#Q;IAN-\$\ZVRMS8XFA8=1CJ/R_E6GI%^NJ:5;7B_\M4!(]#W'YUM/WDI_>.'
MN0E+M%%9&AP_C/XCZ?H5K>6=B\EQJJ@QB-(VQ\$Q'5FQCC.>*P_A3XIT73M"
MCTNZE>#4IKEBWF1-^9CA2& QTP.:]2V*>JC\J-B_P!T?E6G/'EY;#N*S!%+
M-P ,FO%OBSXDT3Q%;6\$>E2/=74\$C\$I\$B8*J\$<C)'/(>TTFQ?[J_E2IS4)<P
M)V/-/A]\1[#^Q+32]:DEM[R#\$,;0&Q65>B\@<'H.?2H/BSXKTR]T&71K*9I[
MT7*#B14C;\$>P\Y.,=>.*]2V+_ '1^5&Q?[H_*J4XJ?-8+ZGG_ ,+_ !7IC^&]
M-T1YFBU&,-&(7C8;^2V0<8Z5#\5/>F-X<0]\$AF:;4'=\$:)(V^3#!B2<8Z"O
M1@BCD*!^%!13U4?E2YUS\U@0J>9?"CQ9IEMX>MM%NIF@00/98XWC;]YN;(P<
M8[U9^*0@J]UR.WU?2\$+WUHNUXU^\Z9R"ON#V[YKT38H_A'Y4ZG[2T^>(7UN>
M?^'?BSI%Q8I#KTK:=J,0VS++&VUF'<8' 'T-5=>\2MX_9?#0A4326TSC[;?["
ML<<8.2 3W=-_<Z587K[[NQM9V_02PJQ_45/!;PVT8CMXHXHQ75%"C\A1S13N
MD!R/C/Q/I'_A_P]>:0TS&[-F8H;=49F(*E5YQC'XUQ/PB\4Z;H%I>V.JR0;/-
M,KQ,T;%6XVXR!P:]F*J3DJ#^%5[R=;. 'S3#04=<8XH4THN-MPOH8_BWQ9I?A
MZQFA09V%S+ QBA5&9GZ@=!CKZUY?)/\$^G^&I-1AU>1[9;@1LDC1L5RN<@X'
M07MX"NJL5'(SS2[\$_NK^5\$9I1<;A?0YGO;XPTC1M+N(;BX)N9[5FAA2-BSA
M@0.V!SZUYQ(_%&G>'!J-MJ\CVPN"CQR-&Q4D @C@<=17MI53U4'*-B_P!U
M?RHC-*+C;<+GE'QDTN[:[T078(3<6ENNV4 9" _N! /L>F:W8?C#X:FL4E#71
MN6 _T182S[00\$<'Z[LJ&!# \$\$8(-5(-)T^UF\ZWL+6*7^D*JWY@4<\7%*2
MV"YX=X]M]536-, \2:U T"WD@98,9^SHC JA/]XC)/OFO1M'UJT\1^ .KC5].D
M:33; '3?)>XVD*79]Y SZ <UV5Q:P7<)BNH8YHCU21 P/X&B"V@M81%;PQPQC
MHD:A0/P%.57FBE8+GB'Q: \3: ?XDGTZ+2)'N5ME=GD\$;!<MC &1[5ZGX4\6:7
MXBLXHK&<FXBA5I861E:/MSD8Z^E;^Q/[J_E2A5'0 ?04I33BHVV!L\7^+GBG
M3?%\$K8V6E20<M!*SRNL;I5XQC')ZUWG@?Q;I6L:1I]A;S\$7T-JJR6[HP(V@
M G.,\$5U>Q?[J_E2,8XL%BB9. 3Q0YIP4; ;! ?0\AN=,0?A?XXDUFWMI;C0;HL
MLIB7)B5CD@^F#R/4<5VLQ/*1V)N1J3C;D1(K&0^VW'6NK(# @@\$'J#5)=
M\$TM90-73; ,29S0\$"Y_/#FI? \$M0N>8>&-#U#QOXZ;Q7JM]MI\;A[.:08+ [>
M\$ 'H.I/<UZ[24M3.?,P;\$)QR>E8>K:Q9V0[R]N\$AA7[JGEG^@ZFLSQQXT@T%
M!8P!I;Z49VH<;%[9/07GC:AJ<TIN&M+*.1N=TRF1_P#QXFM(8:I-77XF%2I)
M:0W.QN?%][? \$QZ+9^6G3S[C^@Z?SJHFD27TPGU:[>Z?_*:-A%^\KFGU071T
MOH4]D@0?TIHU?Q!*<+J<[? [D8_H*OZA-[R1S.FY.]1W_ "/@865HH 0S%>B
M*-B#^IKHM+EN)XS)*BQQ8Q&BC'XUY#%XJG.([C57_W(S_A6K9Z5XXNB MQJ

M48]9KC8!^'6E]4Y=YHWA==#U9U#J5895A@BN;\#,8M.O+,_\NMTZ#Z?YS2>' MO#NJ64RW&KZS<w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

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>